(Q38082848)

28 August 2017

title

Efficacy and safety of Jentadueto® (linagliptin plus metformin). (English)

1 reference

28 August 2017

1 reference

1 reference

André J Scheen

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

Expert Opinion on Drug Safety

28 August 2017

published in

1 reference

28 August 2017

volume

12

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

275-289

1 reference

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Addition of incretin therapy to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Metformin + saxagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Fixed-dose single tablet antidiabetic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Review of linagliptin for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Clinical pharmacokinetics of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Clinical Pharmacokinetics of Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Drug interactions of clinical importance with antihyperglycaemic agents: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Cellular and molecular mechanisms of metformin: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.771631

10.1517/14740338.2013.771631

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference